- Gainesville FL UNITED STATES
- College of Medicine
Dr. Ali Ataya is a critical care physician specializing in treating patients with pulmonary hypertension and rare lung diseases.Contact More Open options
Dr. Ali Ataya is an associate professor of medicine within the Division of Pulmonary, Critical Care and Sleep Medicine. He is the director of the Pulmonary Hypertension Center of Comprehensive Care, director of the Hereditary Hemorrhagic Telangiectasia Center of Excellence, and director of the LAM & Rare Lung Disease Program at UF. His area of expertise and clinical research focuses on helping patients with rare lung diseases.
Areas of Expertise
Unvaccinated, expectant mother nearly dies of COVID-19, becomes vaccine champion
UF Health online
Friends and family gathered at Amy Westman’s July 24 baby shower. Gifts and balloons and bursts of blue brightened the room. Blue cupcakes. Blue bows and wrapping paper. Blue as in boy. Her lovely Nicholas. Amy didn’t give much thought to the coronavirus at the shower. Nicholas was six weeks from his due date. This was a happy time. All these months into the pandemic and she hadn’t gotten sick. Besides, the coronavirus seemed at low ebb.
UF Health among first in world to use novel diaphragmatic pacer to help COVID-19 patients breathe
UF Health online
As the world’s focus shifts from COVID-19 vaccine creation to distribution, researchers and clinicians continue to search for ways to alleviate the suffering of patients and the demands on crowded hospitals. Now, after Emergency Use Authorization approval from the U.S. Food and Drug Administration, University of Florida Health is the first in the Southeast to implant a novel diaphragmatic neurostimulator in a coronavirus patient requiring a ventilator. This is the third instance of this here in the United States.
UF Health earns accreditation as clinic site to treat rare lung disease
UF Health online
The University of Florida College of Medicine’s division of pulmonary, critical care & sleep medicine was recently named the third accredited LAM and Rare Lung Disease clinic site in Florida by the LAM Foundation. The site, which is led by director Mark Brantly, M.D., a professor of medicine, and associate director Ali Ataya, M.D., an assistant professor of medicine, will focus on patients with orphan lung diseases.
Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical reviewPulmonary Circulation
Akash Mathavan, et. al
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant hereditary disorder characterized by recurrent spontaneous epistaxis, mucocutaneous telangiectasias, and solid organ arteriovenous malformations (AVMs). Pulmonary hypertension (PH) is an increasingly recognized complication in patients with HHT, most often precipitated by high-output heart failure in the presence of hepatic AVMs as well as pulmonary arterial hypertension in the form of a proliferative vasculopathy.
COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin InhibitionChest
Bruno Guedes Baldi, et. al
We conducted a retrospective observational study that assessed patients with lymphangioleiomyomatosis receiving care at lymphangioleiomyomatosis clinics in Brazil, the United States, Europe, and Japan who contracted COVID-19 between December 1, 2019, and August 31, 2021. All local institutional ethical committees approved the study.
The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise ReviewFrontiers in Immunology
Ali Ataya, et al.
Autoantibodies to multiple cytokines have been identified and some, including antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), have been associated with increased susceptibility to infection. High levels of GM-CSF autoantibodies that neutralize signaling cause autoimmune pulmonary alveolar proteinosis (aPAP), an ultrarare autoimmune disease characterized by accumulation of excess surfactant in the alveoli, leading to pulmonary insufficiency.
Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart DiseaseJournal of the American Heart Association
Christelle Lteif, Ali Ataya and Julio D. Duarte
Pulmonary hypertension (PH) attributable to left heart disease (LHD) is believed to be the most common form of PH and is strongly associated with increased mortality and morbidity in this patient population. Specific therapies for PH‐LHD have not yet been identified and the use of pulmonary artery hypertension‐targeted therapies in PH‐LHD are not recommended.